FDA to Let Caronia Stand, Will Factor Ruling Into Guidance

The FDA will not seek further review of the 2nd Circuit’s decision in U.S. v. Caronia as the agency doesn’t view the decision as a significant threat to its misbranding enforcement drive. However, the controversial ruling will likely factor into guidance development, FDA officials said Jan. 30.

This article is viewable by subscribers only. To view this article, please select an option below.

Source found here